1207456-01-6

Product Details:

CasNo： 1207456-01-6

Molecular Formula： C19H14F2N6O

Appearance： White to off-white Powder

Packing： Aluminium bag

Throughput： 100KG/Month

Purity： 99%

Physical‑Chemical Properties

Appearance: White to yellow solid / powderDailyMed Sparingly soluble in water; soluble in DMSO and many organic solvents. Light‑sensitive.

Mechanism of Action

Talazoparib tosylate is a highly potent, orally‑bioavailable PARP‑1 and PARP‑2 inhibitor. It exerts dual‑mode anti‑tumour activity: catalytic inhibition of PARP enzyme plus strong PARP‑trapping effect. It locks PARP‑DNA complex at DNA‑strand‑break sites, blocks DNA damage‑repair process. Tumour cells with defective homologous‑recombination‑repair (such as BRCA1 / BRCA2 mutation) cannot repair accumulated DNA double‑strand breaks, leading to cancer‑cell apoptosis and synthetic lethalityEuropean M.... Among marketed PARP inhibitors, talazoparib exhibits outstanding PARP‑trapping potency.

Indications

1. Monotherapy: For adult patients with germline BRCA‑mutated, HER2‑negative locally advanced or metastatic breast cancer (deleterious or suspected deleterious BRCA1/2 mutation)Pfizer Med....
2. Combination therapy with enzalutamide: For adult patients with HRR‑gene‑mutated metastatic castration‑resistant prostate cancer (mCRPC)Pfizer Med....

Note: Patient selection should rely on approved companion diagnostic tests for BRCA or HRR gene alterations.

API Quality Profile

• HPLC Purity: NLT 98.0%
• Total impurities: ≤1.0%, single unknown impurity ≤0.15%
• Loss on drying: ≤0.5%
• COA, HPLC, NMR, MS available for R&D and formulation development. No official EP/USP pharmacopoeia monograph published yet.

Storage & Packing

Store in tightly‑closed container, protect from light, storage temperature ≤30 °C. Long‑term storage recommended at 2‑8 °C. Available packing: 1 g, 5 g, 10 g, 100 g, 1 kg aluminium foil bag / drum for lab‑scale and pilot manufacture.

Disclaimer

This product description serves for pharmaceutical raw‑material reference only, not for clinical medication guidance.